---
layout: post
title: "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability"
date: 2026-02-05 18:58:53 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-08499
original_published: 2022-04-21 00:00:00 +0000
significance: 8.00
---

# Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability

**Published:** February 05, 2026 18:58 UTC
**Source:** Federal Register
**Original Published:** April 21, 2022 00:00 UTC
**Document Number:** 2022-08499

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of the Agency's annual report entitled "Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments." Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA is required to report annually on the status of postmarketing requirements (PMRs) and postmarketing commitments (PMCs) required of, or agreed upon by, application holders of approved drug and biological products. The report on the status of the studies and clinical trials that applicants have agreed, or are required, to conduct is on FDA's "Postmarketing Requirements and Commitments: Reports" web page (https://www.fda.gov/drugs/postmarket- requirements-and-commitments/postmarketing-requirements-and- commitments-reports).

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/04/21/2022-08499/report-on-the-performance-of-drug-and-biologics-firms-in-conducting-postmarketing-requirements-and)
- API: https://www.federalregister.gov/api/v1/documents/2022-08499

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
